65162-437 : Levomilnacipran 80 mg Oral Capsule, Extended Release
| NDC: | 65162-437 |
| Labeler: | Amneal Pharmaceuticals LLC |
| Product Type: | Human Prescription Drug |
| Drug Name: |  Levomilnacipran |
| Dosage Form: | Oral Capsule, Extended Release |
| Application #: | ANDA210790 |
| Rev. Date: |
Appearance:
| Markings: | AN;437 |
| Shapes: |
Capsule |
| Colors: |
 Pink |
| Size (mm): | 18 |
| Segments: * | 1 |
* Segments = the number of equally sized pieces which the pill can be broken into. In this case, a value of 1 indicates a solid pill with no score lines. | |
NDC Package Codes:
- 65162-437-03: 30 CAPSULE, EXTENDED RELEASE IN 1 BOTTLE (65162‑437‑03)
Active Ingredients:
- Levomilnacipran Hydrochloride
Dosage Strength:
- 80 mg
Inactive Ingredients:
- Alcohol
- Ammonia
- Butyl Alcohol
- Ethylcellulose (20 Mpa.s)
- Ferric Oxide Red
- Ferrosoferric Oxide
- Hypromelloses
- Isopropyl Alcohol
- Potassium Hydroxide
- Povidone
- Propylene Glycol
- Shellac
- Starch, Corn
- Sucrose
- Talc
- Titanium Dioxide
- Triethyl Citrate
- Water /
Pharmaceutical Classes:
- Norepinephrine Uptake Inhibitors [MoA]
- Serotonin Uptake Inhibitors [MoA]
- Serotonin and Norepinephrine Reuptake Inhibitor [EPC]
Related Products:
Based on records with the same trade name.- 65162-411 Levomilnacipran 20 mg Oral Capsule, Extended Release by Amneal Pharmaceuticals LLC
- 65162-455 Levomilnacipran 120 mg Oral Capsule, Extended Release by Amneal Pharmaceuticals LLC
- 65162-960 Levomilnacipran 40 mg Oral Capsule, Extended Release by Amneal Pharmaceuticals LLC
NDC QR Code
Scan the QR code below to easily reference this data in the future:
< Prev: 65162-436Next: 65162-438 >
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.